The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
**Background:** Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other payers. **Objectives:** To compare the incidence of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-12-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.124367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860360978890752 |
|---|---|
| author | Prachi Bhatt Jared Hirsch Paul Cockrum George Kim Gabriela Dieguez |
| author_facet | Prachi Bhatt Jared Hirsch Paul Cockrum George Kim Gabriela Dieguez |
| author_sort | Prachi Bhatt |
| collection | DOAJ |
| description | **Background:** Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other payers.
**Objectives:** To compare the incidence of adverse events (AEs), AE-associated excess costs, and total cost of care (TCOC) of 3 cohorts receiving first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
**Methods:** We conducted a retrospective analysis of administrative claims data from 2018 to 2022 using the Medicare 100% Research Identifiable Files. We examined 3 cohorts receiving mPDAC treatment: FOLFIRINOX (FFX) (oxaliplatin, irinotecan, leucovorin, 5-FU bolus and infusion); modified FFX, (5-FU infusion only); and gemcitabine/nab-paclitaxel (gem/abrax). We compared the incidence of clinically significant AEs, TCOC, components of TCOC, and costs related to AEs/treatment toxicity.
**Results:** Patient AE rates ranged from 6.2% to 51.7%. AEs occurred more frequently in patients receiving FFX with all 4 components. Patients receiving brand name gem/abrax had lower rates of febrile neutropenia (6.2%) and neutropenia (22.2%) than those receiving FFX with no 5-FU bolus (febrile neutropenia, 9.9%; neutropenia, 36.9%) and FFX with all 4 components (febrile neutropenia, 6.9%; neutropenia, 30.4%). Rates of most nonhematologic AEs were higher in patients receiving FFX with all 4 components, with diarrhea occurring in 28.3%, abdominal pain in 31.5%, and nausea/vomiting in 41.5% of patients. TCOC was lower in the gem/abrax cohort: $6505 vs FFX with no 5-FU bolus ($6995) and FFX with all 4 components ($7142) per administration. The development of any studied hematologic AE was associated with a mean excess cost of $5993 per administration, while the development of any studied nonhematological AE was associated with a mean per-administration excess cost of $3665.
**Discussion:** Treatment decisions intended to minimize chemotherapy costs may lead to suboptimal decisions if the goal is to reduce TCOC. Our research suggests FFX is more costly than gem/abrax (TCOC per administration). Patients receiving gem/abrax were older and had higher baseline Charlson Comorbidity Index scores; however, other factors may be important in driving cost differences.
**Conclusions:** Irrespective of drug cost, chemotherapy leading to a significant increase in AEs is associated with higher TCOC. |
| format | Article |
| id | doaj-art-981728d2e15f4c05afd6b72dae391b65 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-981728d2e15f4c05afd6b72dae391b652025-02-10T16:12:35ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362024-12-01112The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal AdenocarcinomaPrachi BhattJared HirschPaul CockrumGeorge KimGabriela Dieguez**Background:** Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other payers. **Objectives:** To compare the incidence of adverse events (AEs), AE-associated excess costs, and total cost of care (TCOC) of 3 cohorts receiving first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). **Methods:** We conducted a retrospective analysis of administrative claims data from 2018 to 2022 using the Medicare 100% Research Identifiable Files. We examined 3 cohorts receiving mPDAC treatment: FOLFIRINOX (FFX) (oxaliplatin, irinotecan, leucovorin, 5-FU bolus and infusion); modified FFX, (5-FU infusion only); and gemcitabine/nab-paclitaxel (gem/abrax). We compared the incidence of clinically significant AEs, TCOC, components of TCOC, and costs related to AEs/treatment toxicity. **Results:** Patient AE rates ranged from 6.2% to 51.7%. AEs occurred more frequently in patients receiving FFX with all 4 components. Patients receiving brand name gem/abrax had lower rates of febrile neutropenia (6.2%) and neutropenia (22.2%) than those receiving FFX with no 5-FU bolus (febrile neutropenia, 9.9%; neutropenia, 36.9%) and FFX with all 4 components (febrile neutropenia, 6.9%; neutropenia, 30.4%). Rates of most nonhematologic AEs were higher in patients receiving FFX with all 4 components, with diarrhea occurring in 28.3%, abdominal pain in 31.5%, and nausea/vomiting in 41.5% of patients. TCOC was lower in the gem/abrax cohort: $6505 vs FFX with no 5-FU bolus ($6995) and FFX with all 4 components ($7142) per administration. The development of any studied hematologic AE was associated with a mean excess cost of $5993 per administration, while the development of any studied nonhematological AE was associated with a mean per-administration excess cost of $3665. **Discussion:** Treatment decisions intended to minimize chemotherapy costs may lead to suboptimal decisions if the goal is to reduce TCOC. Our research suggests FFX is more costly than gem/abrax (TCOC per administration). Patients receiving gem/abrax were older and had higher baseline Charlson Comorbidity Index scores; however, other factors may be important in driving cost differences. **Conclusions:** Irrespective of drug cost, chemotherapy leading to a significant increase in AEs is associated with higher TCOC.https://doi.org/10.36469/001c.124367 |
| spellingShingle | Prachi Bhatt Jared Hirsch Paul Cockrum George Kim Gabriela Dieguez The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma Journal of Health Economics and Outcomes Research |
| title | The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma |
| title_full | The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma |
| title_fullStr | The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma |
| title_short | The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma |
| title_sort | effects of adverse events and associated costs on value based care for metastatic pancreatic ductal adenocarcinoma |
| url | https://doi.org/10.36469/001c.124367 |
| work_keys_str_mv | AT prachibhatt theeffectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT jaredhirsch theeffectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT paulcockrum theeffectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT georgekim theeffectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT gabrieladieguez theeffectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT prachibhatt effectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT jaredhirsch effectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT paulcockrum effectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT georgekim effectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma AT gabrieladieguez effectsofadverseeventsandassociatedcostsonvaluebasedcareformetastaticpancreaticductaladenocarcinoma |